Researchers from the US have discovered that the fibrin-targeting monoclonal antibody may neutralize the highly inflammatory blood clots formed by the spike glycoprotein of SARS-CoV-2. This study has revealed a completely new strategy to reduce thrombotic inflammation in COVID-19 infection. One of the most life-threatening complications associated with COVID-19 is the thrombotic cascade of events that represents themselves in the form of blood clots in various organs, increasing mortality and morbidity.
Such complications are often silhouetted under the triad of inflammation, disease severity, and hyper coagulation state. This clinical course is baffling, as not all inflammatory conditions manifest with clotting or thrombotic events. Furthermore, the clotting pathology induced by COVID-19 is found to be resistant against the anti-coagulation efforts, and even young patients with…
